stars 1 stars 2 stars 3

Embleema helps research teams, registries, and patient organizations turn complex real-world data into regulatory-grade evidence. Our platform unifies clinical, molecular, and patient-reported data to accelerate insights, improve study quality, and reduce time to submission. The FDA uses Embleema’s platform for genomic regulatory evaluations and to help shape future CDISC standards for cell and gene therapies. We also power landmark initiatives such as the Lupus Landmark and Human Epilepsy Project, in collaboration with leading research networks including Johns Hopkins, NYU, UCSF, and Mayo Clinic. Whether you’re managing a disease registry, leading a post-market study, or advancing advocacy-driven research, Embleema connects every stakeholder—sites, sponsors, and patients—through one secure, compliant data infrastructure. Learn how Embleema’s regulatory-grade platform can strengthen your research from design to submission. Explore case studies and connect with our team by visiting us at www.embleema.com.

Embleema Questions

Robert Chu is the Co-Founder and CEO of Embleema.

20 people are employed at Embleema.

Embleema is based in New York, New York.

Top Embleema Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users